Abordando los desafíos de la EPOC en Latinoamérica: Preguntas y respuestas basadas en metodología GRADE Recomendaciones EPOC ALAT 2025
Barra lateral del artículo
Contenido principal del artículo
Resumen
Introducción: La enfermedad pulmonar obstructiva crónica (EPOC) representa un importante desafío para la salud pública en América Latina, contribuyendo sustancialmente a la morbilidad y la mortalidad. Este documento busca brindar recomendaciones basadas en la evidencia para el diagnóstico y el tratamiento de la EPOC en América Latina, adaptadas a las necesidades y recursos específicos de la región. Su propósito es servir de guía para los profesionales de la salud en sus esfuerzos por mejorar la calidad de vida de las personas con EPOC.
Metodología: Se estableció el comité ejecutivo de las recomendaciones conformado por cuatro médicos neumólogos miembros del departamento de EPOC de ALAT y dos epidemiólogos clínicos. Representantes de sociedades nacionales de Neumología y representantes de departamentos científicos de ALAT, quienes formularon preguntas clínicas; se seleccionaron 12 preguntas por su relevancia para contexto latinoamericano. Luego, se utilizó el sistema GRADE (Grading of Recommendations Assessment, Development and Evaluation) para evaluar la evidencia disponible y formular las recomendaciones.
Resultados: Se obtuvieron recomendaciones en 12 preguntas PICO divididas en cuatro apartados: prevención secundaria, pronóstico I, pronóstico II y terapéutica.
Conclusiones: El objetivo del presente documento es proporcionar recomendaciones de relevancia para el diagnóstico y tratamiento de la EPOC en Latinoamérica, que sean aplicables para médicos especialistas y de atención primaria con la finalidad de reducir el impacto asistencial y los costos asociados a la enfermedad.
Detalles del artículo
Sección
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Cómo citar
Referencias
Stolz D, Mkorombindo T, Schumann DM et al. Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission. Lancet Lond Engl 2022;400(10356):921-72. https://doi.org/10.1016/S0140-6736(22)01273-9
Polverino F, Bhutani M, Zabert G et al. Access to Treatment for Chronic Obstructive Pulmonary Disease in the Americas: A Call for Action. A Joint Perspective from the Brazilian Thoracic Society, Canadian Thoracic Society, Latin American Thoracic Society, and the American Thoracic Society. Ann Am Thorac Soc 2024;21(11):1463-70. https://doi.org/10.1513/AnnalsATS.202404-386FR
Torres-Duque CA, Jaramillo C, Caballero A et al. Chronic obstructive pulmonary disease related to wood smoke and impact of the combined exposure to tobacco. IJTLD Open 2024;1(3):130-5. https://doi.org/10.5588/ijtldopen.24.0004
Yang IA, Jenkins CR, Salvi SS. Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment. Lancet Respir Med 2022;10(5):497-511. https://doi.org/10.1016/S2213-2600(21)00506-3
Joo H, Yoon HK, Hwang YI et al. Application of the Lancet Commission COPD classification to COPD Cohort Population in South Korea. Respir Med 2024;230:107679. https://doi.org/10.1016/j.rmed.2024.107679
Schünemann HJ, Wiercioch W, Etxeandia I et al. Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise. CMAJ 2014;186(3):E123-142. https://doi.org/10.1503/cmaj.131237
Alonso-Coello P, Schünemann HJ, Moberg J et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. BMJ 2016;353:i2016. https://doi.org/10.1136/bmj.i2016
Alonso-Coello P, Oxman AD, Moberg J et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines. BMJ 2016;353:i2089. https://doi.org/10.1136/bmj.i2089
Guyatt G, Oxman AD, Akl EA et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;64(4):383-94. https://doi.org/10.1016/j.jclinepi.2010.04.026
Guyatt GH, Oxman AD, Vist GE et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6. https://doi.org/10.1136/bmj.39489.470347.AD
Schünemann HJ, Mustafa R, Brozek J et al. GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health. J Clin Epidemiol 2016;76:89-98. https://doi.org/10.1016/j.jclinepi.2016.01.032
Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines; Editors: Graham R, Mancher M, Miller Wolman D, et al. Clinical Practice Guidelines We Can Trust. National Academies Press (US), Washington (DC), 2011.
Freites-Martinez A, Santana N, Arias-Santiago S et al. Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. Actas Dermosifiliogr 2021;112(1):90-2. https://doi.org/10.1016/j.ad.2019.05.009
Kirmayr M, Quilodrán C, Valente B et al. The GRADE approach, Part 1: how to assess the certainty of the evidence. Medwave 2021;21(2):e8109. https://doi.org/10.5867/medwave.2021.02.8109
Khdour MR, Kidney JC, Smyth BM et al. Clinical pharmacy-led disease and medicine management programme for patients with COPD. Br J Clin Pharmacol 2009;68(4):588-98. https://doi.org/10.1111/j.1365-2125.2009.03493.x
Rootmensen GN, van Keimpema ARJ, Looysen EE et al. The effects of additional care by a pulmonary nurse for asthma and COPD patients at a respiratory outpatient clinic: results from a double blind, randomized clinical trial. Patient Educ Couns 2008;70(2):179-86. https://doi.org/10.1016/j.pec.2007.09.021
Xin C, Xia Z, Jiang C et al. The impact of pharmacist-managed clinic on medication adherence and health-related quality of life in patients with COPD: a randomized controlled study. Patient Prefer Adherence 2016;10:1197-203. https://doi.org/10.2147/PPA.S110167
Tommelein E, Mehuys E, Van Hees T et al. Effectiveness of pharmaceutical care for patients with chronic obstructive pulmonary disease (PHARMACOP): a randomized controlled trial. Br J Clin Pharmacol 2014;77(5):756-66. https://doi.org/10.1111/bcp.12242
Göriş S, Taşci S, Elmali F. The effects of training on inhaler technique and quality of life in patients with COPD. J Aerosol Med Pulm Drug Deliv 2013;26(6):336-44. https://doi.org/10.1089/jamp.2012.1017
Bosnic-Anticevich SZ, Sinha H, So S et al. Metered-dose inhaler technique: the effect of two educational interventions delivered in community pharmacy over time. J Asthma 2010;47(3):251-6. https://doi.org/10.3109/02770900903580843
van der Palen J, Klein JJ, Kerkhoff AH et al. Evaluation of the long-term effectiveness of three instruction modes for inhaling medicines. Patient Educ Couns 1997;32(1):S87-95. https://doi.org/10.1016/s0738-3991(97)00100-6
De Blaquiere P, Christensen DB, Carter WB et al. Use and misuse of metered-dose inhalers by patients with chronic lung disease. A controlled, randomized trial of two instruction methods. Am Rev Respir Dis 1989;140(4):910-6. https://doi.org/10.1164/ajrccm/140.4.910
Pitta F, Troosters T, Spruit MA et al. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171(9):972-7. https://doi.org/10.1164/rccm.200407-855OC
Watz H, Waschki B, Meyer T et al. Physical activity in patients with COPD. Eur Respir J 2009;33(2):262-72. https://doi.org/10.1183/09031936.00024608
Mendoza L, de Oca MM, López Varela MV et al. Physical Activity Levels and Associated Factors in a Latin American COPD Population of Patients. The LASSYC Study. COPD 2021;18(4):393-400. https://doi.org/10.1080/15412555.2021.1937090
Waschki B, Kirsten A, Holz O et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest 2011;140(2):331-42. https://doi.org/10.1378/chest.10-2521
Parada A, Klaassen J, Lisboa C et al. [Reduction of physical activity in patients with chronic obstructive pulmonary disease]. Rev Med Chil 2011;139(12):1562-72. http://dx.doi.org/10.4067/S0034-98872011001200005
Esteban C, Quintana JM, Aburto M et al. Impact of changes in physical activity on health-related quality of life among patients with COPD. Eur Respir J 2010;36(2):292-300. https://doi.org/10.1183/09031936.00021409
Shrikrishna D, Patel M, Tanner RJ et al. Quadriceps wasting and physical inactivity in patients with COPD. Eur Respir J 2012;40(5):1115-22. https://doi.org/10.1183/09031936.00170111
Wootton SL, Hill K, Alison JA et al. Effects of ground-based walking training on daily physical activity in people with COPD: A randomised controlled trial. Respir Med 2017;132:139-45. https://doi.org/10.1016/j.rmed.2017.10.008
Hospes G, Bossenbroek L, Ten Hacken NHT et al. Enhancement of daily physical activity increases physical fitness of outclinic COPD patients: results of an exercise counseling program. Patient Educ Couns 2009;75(2):274-8. https://doi.org/10.1016/j.pec.2008.10.005
Arbillaga-Etxarri A, Gimeno-Santos E, Barberan-Garcia A et al. Long-term efficacy and effectiveness of a behavioural and community-based exercise intervention (Urban Training) to increase physical activity in patients with COPD: a randomised controlled trial. Eur Respir J 2018;52(4):1800063. https://doi.org/10.1183/13993003.00063-2018
Vorrink SNW, Kort HSM, Troosters T et al. Efficacy of an mHealth intervention to stimulate physical activity in COPD patients after pulmonary rehabilitation. Eur Respir J 2016;48(4):1019-29. https://doi.org/10.1183/13993003.00083-2016
Mendoza L, Horta P, Espinoza J et al. Pedometers to enhance physical activity in COPD: a randomised controlled trial. Eur Respir J 2015;45(2):347-54. https://doi.org/10.1183/09031936.00084514
Demeyer H, Louvaris Z, Frei A et al. Physical activity is increased by a 12-week semiautomated telecoaching programme in patients with COPD: a multicentre randomised controlled trial. Thorax 2017;72(5):415-23. https://doi.org/10.1136/thoraxjnl-2016-209026
Pleguezuelos E, Pérez ME, Guirao L et al. Improving physical activity in patients with COPD with urban walking circuits. Respir Med 2013;107(12):1948-56. https://doi.org/10.1016/j.rmed.2013.07.008
Lisboa C, Borzone G, Cruz E. [Inspiratory muscle training in patients with chronic obstructive pulmonary disease]. Rev Med Chil 1998;126(5):563-8.
Leiva LE, Lammie PJ. Modulation of lymphocyte activation by soluble Brugia pahangi extracts. Trop Med Parasitol 1989;40(3):327-31.
Similowski T, Yan S, Gauthier AP et al. Contractile properties of the human diaphragm during chronic hyperinflation. N Engl J Med 1991;325(13):917-23. https://doi.org/10.1056/NEJM199109263251304
Ammous O, Feki W, Lotfi T et al. Inspiratory muscle training, with or without concomitant pulmonary rehabilitation, for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev 2023;1(1):CD013778. https://doi.org/10.1002/14651858.CD013778.pub2
Young KA, Strand M, Ragland MF et al. Pulmonary Subtypes Exhibit Differential Global Initiative for Chronic Obstructive Lung Disease Spirometry Stage Progression: The COPDGene® Study. Chronic Obstr Pulm Dis 2019;6(5):414-29. https://doi.org/10.15326/jcopdf.6.5.2019.0155
Wijnant SRA, De Roos E, Kavousi M et al. Trajectory and mortality of preserved ratio impaired spirometry: the Rotterdam Study. Eur Respir J 2020;55(1):1901217. https://doi.org/10.1183/13993003.01217-2019
Perez-Padilla R, Montes de Oca M, Thirion-Romero I et al. Trajectories of Spirometric Patterns, Obstructive and PRISm, in a Population-Based Cohort in Latin America. Int J Chron Obstruct Pulmon Dis 2023;18:1277-85. https://doi.org/10.2147/COPD.S406208
Park HJ, Byun MK, Rhee CK et al. Significant predictors of medically diagnosed chronic obstructive pulmonary disease in patients with preserved ratio impaired spirometry: a 3-year cohort study. Respir Res 2018;19(1):185. https://doi.org/10.1186/s12931-018-0896-7
Hersh CP, DeMeo DL, Al-Ansari E et al. Predictors of survival in severe, early onset COPD. Chest 2004;126(5):1443-51. https://doi.org/10.1378/chest.126.5.1443
Anthonisen NR, Skeans MA, Wise RA et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005;142(4):233-9. https://doi.org/10.7326/0003-4819-142-4-200502150-00005
Li X, Wu Z, Xue M et al. Smoking status affects clinical characteristics and disease course of acute exacerbation of chronic obstructive pulmonary disease: A prospectively observational study. Chron Respir Dis 2020;17:1479973120916184. https://doi.org/10.1177/1479973120916184
Kang HR, Kim SJ, Nam JG et al. Impact of Smoking and Chronic Obstructive Pulmonary Disease on All-Cause, Respiratory, and Cardio-Cerebrovascular Mortality. Int J Chron Obstruct Pulmon Dis 2024;19:1261-72. https://doi.org/10.2147/COPD.S458356
Montes de Oca M, Laucho-Contreras ME. Smoking cessation and vaccination. Eur Respir Rev Off J Eur Respir Soc 2023;32(167):220187. https://doi.org/10.1183/16000617.0187-2022
Anthonisen NR, Connett JE, Kiley JP et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994;272(19):1497-505. https://doi.org/10.1001/jama.1994.03520190043033
Tashkin DP, Celli B, Kesten S et al. Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. Eur Respir J 2010;35(2):287-94. https://doi.org/10.1183/09031936.00082909
Tashkin DP, Goodin T, Bowling A et al. Effect of smoking status on lung function, patient-reported outcomes, and safety among COPD patients treated with glycopyrrolate inhalation powder: pooled analysis of GEM1 and GEM2 studies. Respir Res 2019;20(1):135. https://doi.org/10.1186/s12931-019-1112-0
Calverley PMA, Anderson JA, Brook RD et al. Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. Am J Respir Crit Care Med 2018;197(1):47-55. https://doi.org/10.1164/rccm.201610-2086OC
Pauwels RA, Löfdahl CG, Laitinen LA et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999;340(25):1948-53. https://doi.org/10.1056/NEJM199906243402503
Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980;93(3):391-8. https://doi.org/10.7326/0003-4819-93-3-391
Report of the Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet Lond Engl 1981;1(8222):681-6. https://doi.org/10.1016/S0140-6736(81)91970-X
Magnet FS, Storre JH, Windisch W. Home oxygen therapy: evidence versus reality. Expert Rev Respir Med 2017;11(6):425-41. https://doi.org/10.1080/17476348.2017.1325323
Jacobs SS, Krishnan JA, Lederer DJ et al. Home Oxygen Therapy for Adults with Chronic Lung Disease. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2020;202(10):e121-41. https://doi.org/10.1164/rccm.202009-3608ST
McDonald CF, Serginson J, AlShareef S et al. Thoracic Society of Australia and New Zealand clinical practice guideline on adult home oxygen therapy. Respirol Carlton Vic 2024;29(9):765-84. https://doi.org/10.1111/resp.14793
Hardinge M, Annandale J, Bourne S et al. British Thoracic Society guidelines for home oxygen use in adults. Thorax 2015;70(Suppl 1):i1-43. https://doi.org/10.1136/thoraxjnl-2015-206865
Fletcher EC, Luckett RA, Goodnight-White S et al. A double-blind trial of nocturnal supplemental oxygen for sleep desaturation in patients with chronic obstructive pulmonary disease and a daytime PaO2 above 60 mm Hg. Am Rev Respir Dis 1992;145(5):1070-6. https://doi.org/10.1164/ajrccm/145.5.1070
Chaouat A, Weitzenblum E, Kessler R et al. A randomized trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease patients. Eur Respir J 1999;14(5):1002-8. https://doi.org/10.1183/09031936.99.14510029
Górecka D, Gorzelak K, Sliwiński P et al. Effect of long-term oxygen therapy on survival in patients with chronic obstructive pulmonary disease with moderate hypoxaemia. Thorax 1997;52(8):674-9. https://doi.org/10.1136/thx.52.8.674
Moore RP, Berlowitz DJ, Denehy L et al. A randomised trial of domiciliary, ambulatory oxygen in patients with COPD and dyspnoea but without resting hypoxaemia. Thorax 2011;66(1):32-7. https://doi.org/10.1136/thx.2009.132522
Albert RK, Au DH, et al.; Long-Term Oxygen Treatment Trial Research Group. A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. N Engl J Med 2016;375(17):1617-27. https://doi.org/10.1056/NEJMoa1604344
Ringbaek T, Martinez G, Lange P. The long-term effect of ambulatory oxygen in normoxaemic COPD patients: a randomised study. Chron Respir Dis 2013;10(2):77-84. https://doi.org/10.1177/1479972312473135
Lacasse Y, Sériès F, Corbeil F et al. Randomized Trial of Nocturnal Oxygen in Chronic Obstructive Pulmonary Disease. N Engl J Med 2020;383(12):1129-38. https://doi.org/10.1056/NEJMoa2013219
Sun L, Chang YF, Wang YF et al. Prognostic value of oxygen inhalation therapy for simple nocturnal hypoxemia in COPD: a meta-analysis. Front Pharmacol 2023;14:1123945. https://doi.org/10.3389/fphar.2023.1123945
Ekström M, Andersson A, Papadopoulos S et al. Long-Term Oxygen Therapy for 24 or 15 Hours per Day in Severe Hypoxemia. N Engl J Med 2024;391(11):977-88. https://doi.org/10.1056/NEJMoa2402638
McDonald CF, Blyth CM, Lazarus MD et al. Exertional oxygen of limited benefit in patients with chronic obstructive pulmonary disease and mild hypoxemia. Am J Respir Crit Care Med 1995;152(5 Pt 1):1616-9. https://doi.org/10.1164/ajrccm.152.5.7582304
Ejiofor SI, Bayliss S, Gassamma A et al. Ambulatory Oxygen for Exercise-Induced Desaturation and Dyspnea in Chronic Obstructive Pulmonary Disease (COPD): Systematic Review and Meta-Analysis. Chronic Obstr Pulm Dis 2016;3(1):419-34. https://doi.org/10.15326/jcopdf.3.1.2015.0146
Ameer F, Carson KV, Usmani ZA et al. Ambulatory oxygen for people with chronic obstructive pulmonary disease who are not hypoxaemic at rest. Cochrane Database Syst Rev 2014;2014(6):CD000238. https://doi.org/10.1002/14651858.CD000238.pub2
Hasegawa T, Ochi T, Goya S et al. Efficacy of supplemental oxygen for dyspnea relief in patients with advanced progressive illness: A systematic review and meta-analysis. Respir Investig 2023;61(4):418-37. https://doi.org/10.1016/j.resinv.2023.03.005
Khor YH, Wong R, McDonald CF. Post-Hospitalization Short-Term Oxygen Therapy: Use of a Clinical Management Pathway and Long-Term Follow-Up. Respir Care 2019;64(3):272-8. https://doi.org/10.4187/respcare.06303
Oba Y, Salzman GA, Willsie SK. Reevaluation of continuous oxygen therapy after initial prescription in patients with chronic obstructive pulmonary disease. Respir Care 2000;45(4):401-6.
Wiener RS, Ouellette DR, Diamond E et al. An official American Thoracic Society/American College of Chest Physicians policy statement: the Choosing Wisely top five list in adult pulmonary medicine. Chest 2014;145(6):1383-91. https://doi.org/10.1378/chest.14-0670
Montes de Oca M, López Varela MV, Acuña A et al. Incorporating New Evidence on Inhaled Medications in COPD. The Latin American Chest Association (ALAT) 2019. Arch Bronconeumol 2020;56(2):106-13. https://doi.org/10.1016/j.arbres.2019.09.023
Chapman KR, Ringdal N, Backer V et al. Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers. Can Respir J 1999;6(1):45-51. https://doi.org/10.1155/1999/894803
López-Campos JL, Carrasco-Hernández L, Román Rodríguez L et al. The clinical implications of triple therapy in fixed-dose combination in COPD: from the trial to the patient. Arch Bronconeumol 2020;56(4):242-8. https://doi.org/10.1016/j.arbr.2020.02.002
Sposato B, Ricci A, Lacerenza LG et al. Triple Therapy in COPD in Real Life: Is It Better to Use Single or Multiple Inhalers? J Clin Med 2024;13(20):6191. https://doi.org/10.3390/jcm13206191
Zhang S, King D, Rosen VM et al. Impact of Single Combination Inhaler versus Multiple Inhalers to Deliver the Same Medications for Patients with Asthma or COPD: A Systematic Literature Review. Int J Chron Obstruct Pulmon Dis 2020;15:417-38. https://doi.org/10.2147/COPD.S234823
Halpin DMG, Rothnie KJ, Banks V et al. Comparative Adherence and Persistence of Single- and Multiple-Inhaler Triple Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care Setting. Int J Chron Obstruct Pulmon Dis 2022;17:2417-29. https://doi.org/10.2147/COPD.S370540
Bremner PR, Birk R, Brealey N et al. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study. Respir Res 2018;19(1):19. https://doi.org/10.1186/s12931-018-0724-0
Ferguson GT, Brown N, Compton C et al. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials. Respir Res 2020;21(1):131. https://doi.org/10.1186/s12931-020-01360-w
Ferguson GT, Rabe KF, Martinez FJ et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med 2018;6(10):747-58. https://doi.org/10.1016/S2213-2600(18)30327-8
Halpin DMG, Worsley S, Ismaila AS et al. INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice. ERJ Open Res 2021;7(2):00950-2020. https://doi.org/10.1183/23120541.00950-2020
Salvi S, Balki A, Krishnamurthy S et al. Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial. ERJ Open Res 2021;7(3):00255-2021. https://doi.org/10.1183/23120541.00255-2021
Vestbo J, Papi A, Corradi M et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet Lond Engl 2017;389(10082):1919-29. https://doi.org/10.1016/S0140-6736(17)30188-5
Vogelmeier CF, Beeh KM, Schultze M et al. Evaluation of Adherence and Persistence to Triple Therapy in Patients with COPD: A German Claims Data Study. Int J Chron Obstruct Pulmon Dis 2024;19:1835-48. https://doi.org/10.2147/COPD.S460903
Mannino D, Bogart M, Wu B et al. Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: A real-world study. Respir Med 2022;197:106807. https://doi.org/10.1016/j.rmed.2022.106807
Lin L, Liu C, Cheng W et al. Comparison of treatment persistence, adherence, and risk of exacerbation in patients with COPD treated with single-inhaler versus multiple-inhaler triple therapy: A prospective observational study in China. Front Pharmacol 2023;14:1147985. https://doi.org/10.3389/fphar.2023.1147985
Gessner C, Trinkmann F, Bahari Javan S et al. Effectiveness of Extrafine Single Inhaler Triple Therapy in Chronic Obstructive Pulmonary Disease (COPD) in Germany - The TriOptimize Study. Int J Chron Obstruct Pulmon Dis 2022;17:3019-31. https://doi.org/10.2147/COPD.S382405
Deslee G, Fabry-Vendrand C, Poccardi N et al. Use and persistence of single and multiple inhaler triple therapy prescribed for patients with COPD in France: a retrospective study on THIN database (OPTI study). BMJ Open Respir Res 2023;10(1):e001585. https://doi.org/10.1136/bmjresp-2022-001585
Brusselle G, Himpe U, Fievez P et al. Evolving to a single inhaler extrafine LABA/LAMA/ICS - Inhalation technique and adherence at the heart of COPD patient care (TRIVOLVE). Respir Med 2023;218:107368. https://doi.org/10.1016/j.rmed.2023.107368
Alcázar-Navarrete B, Jamart L, Sánchez-Covisa J et al. Clinical Characteristics, Treatment Persistence, and Outcomes Among Patients With COPD Treated With Single- or Multiple-Inhaler Triple Therapy: A Retrospective Analysis in Spain. Chest 2022;162(5):1017-29. https://doi.org/10.1016/j.chest.2022.06.033
Bogart M, Bengtson LGS, Johnson MG et al. Outcomes Following Initiation of Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol versus Multiple-Inhaler Triple Therapy Among Medicare Advantage with Part D Beneficiaries and Those Commercially Enrolled for Health Care Insurance in the United States. Int J Chron Obstruct Pulmon Dis 2024;19:97-110. https://doi.org/10.2147/COPD.S424497
Celli BR, Fabbri LM, Aaron SD et al. An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal. Am J Respir Crit Care Med 2021;204(11):1251-8. https://doi.org/10.1164/rccm.202108-1819PP
Amado Diago CA, Figueira Gonçalves JM, Golpe R et al. Classification of the Severity of COPD Exacerbations in Hospitalized Patients According to Rome vs GesEPOC Criteria. Arch Bronconeumol 2023;59(1):57-8. https://doi.org/10.1016/j.arbres.2022.06.009
Jacobson PK, Lind L, Persson HL. Applying the Rome Proposal on Exacerbations of Chronic Obstructive Pulmonary Disease: Does Comorbid Chronic Heart Failure Matter? Int J Chron Obstruct Pulmon Dis 2023;18:2055-64. https://doi.org/10.2147/COPD.S425592
Lee HJ, Lee JK, Park TY et al. Validation of the Rome proposal for severity of acute exacerbation of chronic obstructive pulmonary disease. Ther Adv Respir Dis 2023;17:17534666231172917. https://doi.org/10.1177/17534666231172917
Reumkens C, Endres A, Simons SO et al. Application of the Rome severity classification of COPD exacerbations in a real-world cohort of hospitalised patients. ERJ Open Res 2023;9(3):00569-2022. https://doi.org/10.1183/23120541.00569-2022
Cortes A, Cureño A, Elizondo A, Hernández R, Carranza J. Impacto de las exacerbaciones en la enfermedad pulmonar obstructiva crónica. Exacerbaciones en la EPOC. Respirar 2023;15(2):113-127. https://doi.org/10.55720/respirar.15.2.5
Tønnesen P. Smoking cessation and COPD. Eur Respir Rev 2013;22(127):37-43. https://doi.org/10.1183/09059180.00007212
Jiménez Ruiz CA, Ramos Pinedo A, Cicero Guerrero A et al. Characteristics of COPD smokers and effectiveness and safety of smoking cessation medications. Nicotine Tob Res 2012;14(9):1035-9. https://doi.org/10.1093/ntr/nts001
Jiménez-Ruiz CA, Riesco Miranda JA, Altet Gómez N et al. Treatment of smoking in smokers with chronic obstructive pulmonary disease. Sociedad Española de Neumología y Cirugía Torácica (SEPAR). Arch Bronconeumol 2013;49(8):354-63. https://doi.org/10.1016/j.arbres.2013.02.005
Warnier MJ, van Riet EES, Rutten FH et al. Smoking cessation strategies in patients with COPD. Eur Respir J 2013;41(3):727-34. https://doi.org/10.1183/09031936.00014012
Chen J, Chen Y, Chen P et al. Effectiveness of individual counseling for smoking cessation in smokers with chronic obstructive pulmonary disease and asymptomatic smokers. Exp Ther Med 2014;7(3):716-20. https://doi.org/10.3892/etm.2013.1463
Hilberink SR, Jacobs JE, Bottema BJAM et al. Smoking cessation in patients with COPD in daily general practice (SMOCC): six months’ results. Prev Med 2005;41(5-6):822-7. https://doi.org/10.1016/j.ypmed.2005.08.003
Lei S, Li M, Duan W et al. The long-term outcomes of tobacco control strategies based on the cognitive intervention for smoking cessation in COPD patients. Respir Med 2020;172:106155. https://doi.org/10.1016/j.rmed.2020.106155
Lou P, Zhu Y, Chen P et al. Supporting smoking cessation in chronic obstructive pulmonary disease with behavioral intervention: a randomized controlled trial. BMC Fam Pract 2013;14:91. https://doi.org/10.1186/1471-2296-14-91
Pederson LL, Wanklin JM, Lefcoe NM. The effects of counseling on smoking cessation among patients hospitalized with chronic obstructive pulmonary disease: a randomized clinical trial. Int J Addict 1991;26(1):107-19. https://doi.org/10.3109/10826089109056242
Wilson JS, Fitzsimons D, Bradbury I et al. Does additional support by nurses enhance the effect of a brief smoking cessation intervention in people with moderate to severe chronic obstructive pulmonary disease? A randomised controlled trial. Int J Nurs Stud 2008;45(4):508-17. https://doi.org/10.1016/j.ijnurstu.2006.10.001
Perez-Padilla R, Fernandez R, Lopez Varela MV et al. Airflow obstruction in never smokers in five Latin American cities: the PLATINO study. Arch Med Res 2012;43(2):159-65. https://doi.org/10.1016/j.arcmed.2012.03.007
Pike WJ, Cockayne A, Webster CA et al. Development and design of a novel in vivo chamber implant for the analysis of microbial virulence and assessment of antimicrobial therapy. Microb Pathog 1991;10(6):443-50. https://doi.org/10.1016/0882-4010(91)90109-n
Ivey MA, Smith SM, Benke G et al. COPD in Never-Smokers: BOLD Australia Study. Int J Chron Obstruct Pulmon Dis 2024;19:161-74. https://doi.org/10.2147/COPD.S439307
Dutta J, Singh S, Greeshma MV et al. Diagnostic Challenges and Pathogenetic Differences in Biomass-Smoke-Induced versus Tobacco-Smoke-Induced COPD: A Comparative Review. Diagn Basel Switz 2024;14(19):2154. https://doi.org/10.3390/diagnostics14192154
Fekete M, Horvath A, Santa B et al. Analysis of COPD: Distinguishing Characteristics and Management of Smoking vs Never Smoking Patients. Int J Chron Obstruct Pulmon Dis 2024;19:2671-88. https://doi.org/10.2147/COPD.S484664
García Morales OM, Cañas-Arboleda A, Rodríguez Malagón MN et al. Blood eosinophils levels in a Colombian cohort of biomass-and tobacco-related COPD patients. Front Med 2024;11:1321371. https://doi.org/10.3389/fmed.2024.1321371
Giraldo-Montoya ÁM, Torres-Duque CA, Giraldo-Cadavid LF et al. Sputum Biomarkers in Wood and Tobacco Smoke Etiotypes of Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis 2024;19:1-10. https://doi.org/10.2147/COPD.S439064
Gutiérrez-Romero KJ, Falfán-Valencia R, Ramírez-Venegas A et al. Altered levels of IFN-γ, IL-4, and IL-5 depend on the TLR4 rs4986790 genotype in COPD smokers but not those exposed to biomass-burning smoke. Front Immunol 2024;15:1411408. https://doi.org/10.3389/fimmu.2024.1411408
Pérez-Padilla R, Ramirez-Venegas A, Sansores-Martinez R. Clinical Characteristics of Patients With Biomass Smoke-Associated COPD and Chronic Bronchitis, 2004-2014. Chronic Obstr Pulm Dis 2014;1(1):23-32. https://doi.org/10.15326/jcopdf.1.1.2013.0004
Ramírez-Venegas A, Montiel-Lopez F, Pérez Lara-Albisua JL et al. Association between chronic obstructive pulmonary disease and biomass smoke in rural areas. Int J Tuberc Lung Dis 2022;26(12):1191-3. https://doi.org/10.5588/ijtld.22.0337
Torres-Duque CA, García-Rodriguez MC, González-García M. Is Chronic Obstructive Pulmonary Disease Caused by Wood Smoke a Different Phenotype or a Different Entity? Arch Bronconeumol 2016;52(8):425-31. https://doi.org/10.1016/j.arbres.2016.04.004
Dharmage SC, Bui DS, Walters EH et al. Lifetime spirometry patterns of obstruction and restriction, and their risk factors and outcomes: a prospective cohort study. Lancet Respir Med 2023;11(3):273-82. https://doi.org/10.1016/S2213-2600(22)00364-2
Seo W, Kim HW, Kim JS et al. Long term management of people with post-tuberculosis lung disease. Korean J Intern Med 2024;39(1):7-24. https://doi.org/10.3904/kjim.2023.395
Kamenar K, Hossen S, Gupte AN et al. Previous tuberculosis disease as a risk factor for chronic obstructive pulmonary disease: a cross-sectional analysis of multicountry, population-based studies. Thorax 2022;77(11):1088-97. https://doi.org/10.1136/thoraxjnl-2020-216500
Fan H, Wu F, Liu J et al. Pulmonary tuberculosis as a risk factor for chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ann Transl Med 2021;9(5):390. https://doi.org/10.21037/atm-20-4576
Konstantinidis I, Zou RH, Papageorgiou SN et al. Effect of Human Immunodeficiency Virus on Lung Function and Structure: A Systematic Review and Meta-Analysis. Ann Am Thorac Soc 2025;22(2):274-84. https://doi.org/10.1513/AnnalsATS.202404-384OC
Ramírez-Venegas A, Velázquez-Uncal M, Aranda-Chávez A et al. Bronchodilators for hyperinflation in COPD associated with biomass smoke: clinical trial. Int J Chron Obstruct Pulmon Dis 2019;14:1753-62. https://doi.org/10.2147/COPD.S201314
González-García M, Torres-Duque CA, Bustos A et al. Bronchial hyperresponsiveness in women with chronic obstructive pulmonary disease related to wood smoke. Int J Chron Obstruct Pulmon Dis 2012;7:367-73. https://doi.org/10.2147/COPD.S30410
Ramírez-Venegas A, Montiel-Lopez F, Robles-Hernández RE et al. Effectiveness of ICS/LABA and LAMA/LABA in COPD due to biomass. ERJ Open Res 2024;10(6):00154-2024. https://doi.org/10.1183/23120541.00154-2024
Huang TM, Kuo KC, Wang YH et al. Risk of active tuberculosis among COPD patients treated with fixed combinations of long-acting beta2 agonists and inhaled corticosteroids. BMC Infect Dis 2020;20(1):706. https://doi.org/10.1186/s12879-020-05440-6
Kim JH, Park JS, Kim KH et al. Inhaled corticosteroid is associated with an increased risk of TB in patients with COPD. Chest 2013;143(4):1018-24. https://doi.org/10.1378/chest.12-1225
Lee CM, Heo J, Han SS et al. Inhaled Corticosteroid-Related Tuberculosis in the Real World Among Patients with Asthma and COPD: A 10-Year Nationwide Population-Based Study. J Allergy Clin Immunol Pract 2019;7(4):1197-1206.e3. https://doi.org/10.1016/j.jaip.2018.10.007
Shu CC, Wu HD, Yu MC et al. Use of high-dose inhaled corticosteroids is associated with pulmonary tuberculosis in patients with chronic obstructive pulmonary disease. Medicine (Baltimore) 2010;89(1):53-61. https://doi.org/10.1097/MD.0b013e3181cafcd3
Sciurba FC, Criner GJ, Christenson SA et al. Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype. N Engl J Med 2025;392(17):1710-20. https://doi.org/10.1056/NEJMoa2413181
Bhatt SP, Rabe KF, Hanania NA et al. Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation. N Engl J Med 2024;390(24):2274-83. https://doi.org/10.1056/NEJMoa2401304
Bhatt SP, Rabe KF, Hanania NA et al. Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts. N Engl J Med 2023;389(3):205-14. https://doi.org/10.1056/NEJMoa2303951
Anzueto A, Barjaktarevic IZ, Siler TM et al. Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials). Am J Respir Crit Care Med 2023;208(4):406-16. https://doi.org/10.1164/rccm.202306-0944OC
Sciurba FC, Christenson SA, Rheault T et al. Effect of Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine on Exacerbation Rate and Risk in Patients With Moderate to Severe COPD. Chest 2025;167(2):425-35. https://doi.org/10.1016/j.chest.2024.07.168
Posthuma R, Van Der Molen MC, Hartman JE et al. Treatable traits in advanced emphysema patients eligible for bronchoscopic lung volume reduction with endobronchial valves. Respir Med 2024;224:107558. https://doi.org/10.1016/j.rmed.2024.107558
Buttery SC, Banya W, Bilancia R et al. Lung volume reduction surgery versus endobronchial valves: a randomised controlled trial. Eur Respir J 2023;61(4):2202063. https://doi.org/10.1183/13993003.02063-2022
Roodenburg SA, Hartman JE, Deslée G et al. Bronchoscopic Lung Volume Reduction Coil Treatment for Severe Emphysema: A Systematic Review and Meta-Analysis of Individual Participant Data. Respiration 2022;101(7):697-705. https://doi.org/10.1159/000524148